Angioplasty or stenting for deep venous thrombosis.
Ronald Lg Flumignan, Luis Cu Nakano, Carolina Dq Flumignan...
https://pubmed.ncbi.nlm.nih.gov/39968829/Actively Recruiting
Led by Inari Medical · Updated on 2026-11-03
300
Participants Needed
64
Research Sites
26 weeks
Total Duration
Researchers are evaluating two treatment strategies for patients with symptomatic unilateral iliofemoral deep vein thrombosis DVT. This prospective, multicenter, randomized controlled trial compares an interventional approach using the ClotTriever System to achieve and maintain vessel openness against conservative medical management relying on anticoagulation therapy alone. The study aims to collect detailed data on patient demographics, comorbidities, diagnosis, treatment, and clinical outcomes over a six-month follow-up period. Participants will be randomly assigned to one of two groups the ClotTriever Intervention Arm, where the device is used to remove blood clots mechanically, or the Conservative Medical Management Arm, where patients receive anticoagulation medications such as Heparin Sodium, Coumadin, Rivaroxaban, or Apixaban. The trial includes approximately 300 subjects and evaluates treatments delivered according to the assigned strategy for symptomatic unilateral iliofemoral DVT. During the study, participants will be monitored through regular assessments including clinical evaluations and measurement of outcomes such as a composite clinical endpoint assessed at 10 days and at 180 days post-treatment. Researchers will also assess the severity of post-thrombotic syndrome PTS at 180 days. Data collection includes demographics and clinical details relevant to DVT diagnosis and management. Safety and efficacy will be monitored through follow-up visits over a six-month period to understand treatment impact and patient outcomes.
CONDITIONS
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
M
Mark Sung
S
Sara Willis
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Inari Medical
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | ClotTriever mechanical thrombectomy | Anticoagulation alone (trial arm) | Anticoagulation alone (guideline‑recommended care) |
|---|---|---|---|
| What it is | A mechanical thrombectomy device (ClotTriever) used to remove clot from iliofemoral veins in addition to anticoagulation | Use of commercially available anticoagulation (e.g. heparin, warfarin, direct oral anticoagulants) | Anticoagulation alone is the guideline‑recommended treatment for acute iliofemoral DVT |
| Role in trial | Investigational active comparator; device arm | Control arm using anticoagulation | Current standard‑of‑care comparator not randomized in trial |
| Primary use | To remove thrombus mechanically in addition to anticoagulation | To prevent clot progression and embolism via anticoagulation | Prevent clot progression and reduce risk of embolism as standard care |
| How it is performed | Mechanical removal of clot using the ClotTriever device in affected veins | Administration of anticoagulant medications typical of standard practice | Standard use of anticoagulation medications following guidelines |
| Evidence status | Under evaluation for efficacy and safety in this randomized trial | Well‑established efficacy in preventing thrombus extension and embolism | Recommended first‑line treatment according to international guidelines |
| Important risks | Potential procedural risks including bleeding or vascular injury; full safety profile pending trial results | Risks include bleeding based on anticoagulant therapy | Bleeding is a known risk of standard anticoagulation therapy |
| Important limitations | Clinical benefits and long‑term outcomes such as PTS reduction are not yet established; procedural risks and late patency unknown | Does not remove clot; post‑thrombotic syndrome may still develop despite therapy | Anticoagulation alone may not prevent post‑thrombotic syndrome in all patients |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Ronald Lg Flumignan, Luis Cu Nakano, Carolina Dq Flumignan...
https://pubmed.ncbi.nlm.nih.gov/39968829/Steven D Abramowitz, Xhorlina Marko, Donna D'Souza...
https://pubmed.ncbi.nlm.nih.gov/39491572/Inari Medical
Lead Sponsor